Aspire Biopharma dismisses auditor Turner Stone, taps CBIZ as replacement
ASBP•Aspire Biopharma dismissed Turner Stone effective Sept. 24, 2026, and engaged CBIZ CPAs as auditor for fiscal 2026; Turner’s 2025 audit report included a going-concern paragraph.
1. Auditor change
Aspire Biopharma’s audit committee engaged CBIZ CPAs as the company’s new auditor for fiscal 2026, effective immediately, after dismissing Turner Stone effective Sept. 24, 2026. Turner’s audit report for 2025 included a going-concern paragraph, and Aspire reported material weaknesses in internal control over financial reporting in its 2025 Form 10-K. The company reported no accounting or auditing disputes with Turner through Sept. 24, 2026.
